title: Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer's Disease Through an Anti-Inflammatory Pathway.
abstract: BACKGROUND
  Dyslipidemia is a risk factor for the pathogenesis of Alzheimer's disease. Although, atorvastatin is a well-accepted lipid-lowering agent, the benefits of atorvastatin treatment through an anti-inflammatory mechanism are still unclear.
  
  
  OBJECTIVE
  The present study was designed to examine changes in inflammatory markers following administration of atorvastatin in dyslipidemic patients with a parental history of Alzheimer's disease.
  
  
  METHODS
  Dyslipidemic adults with a parental history of Alzheimer's disease were administered either 40 mg of atorvastatin or placebo for 18 months. Before and after the study, lpid levels, blood pressure, body weight and body mass index, and the inflammatory markers hs-Creactive protein, serum monocyte chemoattractant protien-1, interleukin-1β, interleukin-6, and tumor necrosis factor-α were tested.
  
  
  RESULTS
  Baseline levels of lipids, body mass index, hs-Creactive protein, monocyte chemoattractant protien-1, interleukin- 1β, interleukin-6 and tumor necrosis factor-α did not show any difference between the two groups. However, after 18 months of atorvastatin treatment, all inflammatory markers significantly decreased in association with a reduction of lipid profiles, body mass index, bodyweight, and blood pressure, compared with those patients treated with placebo.
  
  
  CONCLUSIONS
  Administration of atorvastatin corrected dyslipidemia in association with a reduction in inflammatory markers. Our results suggest that the therapeutic benefits of atorvastatin possibly involve an anti-inflammatory pathway.
authors.forename: Liandong
authors.initials: L
authors.lastname: Zhao
authors.forename: Qitao
authors.initials: Q
authors.lastname: Zhao
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhou
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China. qi_wan@126.com.
authors.forename: Qi
authors.initials: Q
authors.lastname: Wan
mesh_terms: D000328:Adult; D000544:Alzheimer Disease / Q000097:blood* / Q000188:drug therapy* / Q000453:epidemiology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000069059:Atorvastatin / Q000494:pharmacology / Q000627:therapeutic use*; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D000893:Anti-Inflammatory Agents; D000924:Anticholesteremic Agents; D018836:Inflammation Mediators; D000069059:Atorvastatin